Linklaters advises the EIC Fund on its participation to the equity funding round of XENOTHERA

Linklaters has advised the EIC Fund (European Innovation Council Fund) on its participation to XENOTHERA’s €20m equity funding round.

Created in 2014, XENOTHERA is a French biotech developing a technological platform of glyco-humanized polyclonal antibodies, with an expertise in both genetic and immunology. This funding round is mainly led by the EIC Fund and the Nabuboto holding company, but also the French fund Anaxago Capital (Objectif Innovation 18) and the social protection group Malakoff Humanis.

This share capital increase will enable XENOTHERA to accelerate its growth and develop its product portfolio, after a rise in notoriety following the development if its anti-COVID19 treatment, called XAV-19. Created in June 2020, the EIC Fund is a breakthrough initiative from the European Commission to make direct equity and quasi-equity investments (between €500 000 and €15m) in European high impact and deep tech start-ups and scale ups.

Linklaters has advised EIC Fund on several of its investments, notably in Antofénol SAS, Minuendo AS, Demeta SAS, Lixea OÜ, Hiber B.V., EpiEndo Pharmaceuticals ehf., NIL Technology ApS and Corwave SA.

The Linklaters team was led by Darko Adamovic, partner in Energy & Infrastructure and Mehdi Boumedine, Corporate counsel, with Léa Prince Agbodjan, Corporate associate.